Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 5/20 | 0.49 |
| ▸ | GBA1 | P04062 | 5/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13456774 | 1.00 | GJB2 (0.49) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL14418558 | 0.95 | GBA1 (0.46) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL5682296 | 0.95 | GBA1 (0.50) | GJB2GBA1SLC2A1TNFSMPD1 | |
| SCHEMBL13810618 | 0.92 | GJB2 (0.51) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL12085702 | 0.92 | GJB2 (0.51) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL14291824 | 0.89 | GJB2 (0.47) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL15505953 | 0.89 | GJB2 (0.45) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL280129 | 0.89 | GJB2 (0.45) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL14413551 | 0.89 | GJB2 (0.45) | GJB2GBA1SLC2A1SMN1; SMN2TNF | |
| SCHEMBL16731206 | 0.89 | GJB2 (0.45) | GJB2GBA1SLC2A1SMN1; SMN2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063302-A1 | CYCLIC SULFONIUM SALT, METHOD FOR PRODUCTION OF CYCLIC SULFONIUM SALT, AND GLYCOSIDASE INHIBITOR | TAKANO CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063302-A1 | CYCLIC SULFONIUM SALT, METHOD FOR PRODUCTION OF CYCLIC SULFONIUM SALT, AND GLYCOSIDASE INHIBITOR | STS, SI, DDOST | GJB2 2713/4885GBA1 525/4885SLC2A1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.